Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous tumor infiltrating lymphocytes - Essen Biotech

Next Previous
X
Search
Drug Profile

Autologous tumor infiltrating lymphocytes - Essen Biotech

Alternative Names: TIL therapy - Essen Biotech

Latest Information Update: 15 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Essen BioTech
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Adenocarcinoma; Brain cancer; Colorectal cancer; Lung cancer

Most Recent Events

  • 20 Oct 2024 Phase-I/II clinical trials in Brain cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT06640582)
  • 15 Oct 2024 Essen Biotech plans phase-I/II BAH2472 trial for Brain cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (IV) in October 2024 (NCT06640582)
  • 29 Sep 2024 Phase-I/II clinical trials in Colorectal cancer (In adolescents, In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Combination therapy, Late-stage disease) in China (IV) (NCT06530303)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top